J.R. McNair
Of Counsel
John (J.R.) McNair's patent litigation practice covers a broad range of technologies, including pharmaceuticals, veterinary products, chemicals, electronics, and computer software. He has extensive experience litigating pharmaceutical patent cases arising under the Hatch-Waxman Act, including particular specialty in cases involving New Chemical Entities. J.R.'s strong background in technology includes a technical degree in chemical engineering.
Key Matters
J.R.'s pharmaceutical patent litigation experience includes the following representative matters:
- BMS v. Teva, No. 10-805 (D. Del.) – Represent Teva in successfully invalidating patent covering the Hepatitis B drug Baraclude® (entecavir) following trial and appeal.
- Endo v. Watson Laboratories, No. 2:13-cv-192 (E.D. Tex.) – Represent Watson in dispute involving patents covering Fortesta® testosterone gel.
- UCB v. Accord, No. 13-1206 (D. Del.) – Represent several Defendants in dispute involving patent covering epilepsy drug Vimpat® (lacosamide).
- Cephalon v. Celgene, No. 2011-cv-12226 (D. Mass.) – Represent Cephalon in enforcement of patent involving Abraxane®, a formulation of the breast cancer drug paclitaxel.
- Southern Research Institute v. Abon, No. 12-4709 (D.N.J.) – Represent Abon in dispute involving patent covering Clolar® (clofarabine), a drug used to treat leukemia.
- Mallinckrodt v. Watson Laboratories, 2:10-cv-06424 (D.N.J.) – Represent Watson in dispute involving extended release pain medication Exalgo® (hydromorphone hydrochloride).
- AstraZeneca v. Teva, No. 1:10-cv-00018 (D. Del.) – Represent Teva in patent dispute involving Faslodex® (fulvestrant) Injection used to treat breast cancer.
- GlaxoSmithKline v. Barr Laboratories, No. 1:08-cv-00112 (D. Del.) – Represent Barr/Teva in dispute involving patents covering the BPH drug Avodart® (dutasteride).
- Cancer Research Technology v. Barr Laboratories, No. 1:07-cv-00457 (D. Del.) – Represent Barr/Teva in patent dispute involving brain cancer drug Temodar® (temozolomide). After a bench trial, the district court ruled in favor of Mr. McNair’s client.
J.R.'s patent litigation experience outside the pharmaceutical arena includes the following representative matters:
- Camelbak v. Ignite, No. 4:13-cv-04940 (N.D. Cal.) – Represent Ignite in patent dispute involving water bottles.
- Merial v. Velcera (M.D. Ga.; D. Del.) – Represent Velcera in patent dispute involving generic flea and tick veterinary products.
- Chamberlain v. Lear, No. 1:05-cv-03449 (N.D. Ill.) – Represent Lear in patent dispute involving “rolling code” garage door openers.
J.R. also has experience with the U.S. Patent and Trademark Office (PTO). During law school, he interned for two administrative patent judges on the Board of Patent Appeals and Interferences where he drafted opinions evaluating ex parte patent appeals.